A head of precision medicine at a midsize pharma speaks about how their company invests in multiple tools and diagnostics modalities. They are well versed in precision medicine as well as translational medicine, and as such, help coordinate partnerships for drug discovery and an IVD partner in developing a companion diagnostic. They currently see their company spending the most money on research tools, specifically genomics and liquid biopsy, AI, and clinical trial operations. They see the greatest returns in CDx and mature research tools, as these efforts help support drug efficacy and mechanism of action interrogation. On the other hand, they note that the ROI from lab automation tools has not been as high as expected. They expect investments in research tools to continue to grow, especially as technologies mature (namely cell omics), and for companion diagnostics investments to decrease or become more of a steady-state investment given regulation changes. Discovery productivity, decreased drug development timelines, and improved operation efficiencies were key investment drivers.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.